The COVID-19 pandemic highlighted challenges and risks in EU health supply chains. In response, the 𝐁𝐢𝐨𝐌𝐚𝐧𝟒𝐑𝟐 Eurocluster aimed to adapt existing health sector funding to scale up innovation. The direct objective of 𝐁𝐢𝐨𝐌𝐚𝐧𝟒𝐑𝟐 is to foster long-term collaboration at the EU level among SMEs, investors, research organizations, and others in the biomanufacturing and medtech industries through a Eurocluster and 𝙎𝙈𝙀 𝙎𝙪𝙥𝙥𝙤𝙧𝙩 𝙋𝙧𝙤𝙜𝙧𝙖𝙢𝙢𝙚.

Oniria Therapeutics was one of the awarded companies within the 𝘽𝙐𝙎𝙄𝙉𝙀𝙎𝙎 𝙏𝙍𝘼𝙉𝙎𝙁𝙊𝙍𝙈𝘼𝙏𝙄𝙊𝙉 category: a biotech company focused on the development of first-in-class drugs in the field of precision oncology. They aim to fight against the persistence of tumour recurrence by pioneering a novel targeted strategy against the epigenetic enzyme TET2.

"𝐁𝐢𝐨𝐌𝐚𝐧𝟒𝐑𝟐 𝘩𝘢𝘴 𝘩𝘦𝘭𝘱𝘦𝘥 𝘵𝘰 𝘢𝘯𝘢𝘭𝘺𝘴𝘦 𝘵𝘩𝘦 𝘨𝘢𝘱 𝘣𝘦𝘵𝘸𝘦𝘦𝘯 𝘵𝘩𝘦 𝘱𝘳𝘰𝘥𝘶𝘤𝘵 𝘱𝘰𝘴𝘪𝘵𝘪𝘰𝘯𝘪𝘯𝘨 𝘢𝘯𝘥 𝘵𝘩𝘦 𝘦𝘹𝘱𝘦𝘤𝘵𝘦𝘥 𝘦𝘷𝘪𝘥𝘦𝘯𝘤𝘦 𝘱𝘢𝘤𝘬𝘢𝘨𝘦 𝘳𝘦𝘲𝘶𝘪𝘳𝘦𝘥 𝘵𝘰 𝘴𝘶𝘱𝘱𝘰𝘳𝘵 𝘩𝘦𝘢𝘭𝘵𝘩 𝘵𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘺 𝘢𝘴𝘴𝘦𝘴𝘴𝘮𝘦𝘯𝘵 𝘴𝘶𝘣𝘮𝘪𝘴𝘴𝘪𝘰𝘯𝘴, 𝘰𝘱𝘵𝘪𝘮𝘪𝘻𝘪𝘯𝘨 𝘵𝘩𝘦 𝘮𝘢𝘳𝘬𝘦𝘵 𝘢𝘤𝘤𝘦𝘴𝘴/𝘱𝘳𝘪𝘤𝘪𝘯𝘨 𝘴𝘵𝘳𝘢𝘵𝘦𝘨𝘺 𝘣𝘦𝘧𝘰𝘳𝘦 𝘤𝘩𝘰𝘰𝘴𝘪𝘯𝘨 𝘵𝘩𝘦 𝘤𝘰𝘶𝘯𝘵𝘳𝘪𝘦𝘴 𝘸𝘩𝘦𝘳𝘦 𝘵𝘩𝘦 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘵𝘳𝘪𝘢𝘭 𝘸𝘪𝘭𝘭 𝘣𝘦 𝘤𝘰𝘯𝘥𝘶𝘤𝘵𝘦𝘥. 𝘐𝘵 𝘢𝘭𝘴𝘰 𝘩𝘦𝘭𝘱𝘦𝘥 𝘶𝘴 𝘵𝘰 𝘥𝘦𝘧𝘪𝘯𝘦 𝘵𝘩𝘦 𝘤𝘰𝘶𝘯𝘵𝘳𝘪𝘦𝘴 𝘧𝘰𝘳 𝘰𝘶𝘳 𝘗𝘊𝘛 𝘱𝘢𝘵𝘦𝘯𝘵 𝘦𝘯𝘵𝘦𝘳𝘴 𝘕𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘗𝘩𝘢𝘴𝘦𝘴."

We would like to express our gratitude to Oniria Therapeutics for their valuable testimonial. Congratulations for your achievements!